Find An Allergist / Immunologist | Pollen Counts | Journal of Allergy and Clinical Immunology | Annual Meeting   Site Map   Contact   Home    Search
Members Key Resources » AAAAI News AAAAI eNews 2007 Accomplishments Promoting your Practice Order Public Education Materials Disease Management/ Ask the Expert Allergy, Asthma & Immunology Education and Research Trust (ART) Journal of Allergy and Clinical Immunology Member Resources Annual Meeting Executive Staff Contacts Online Membership Directory AAAAI Organizational Structure » Members Contact AAAAI: Professional Home for the Practicing Allergist AAAAI Job Placement Center Grants and Awards Hot Topics Joint Council of Allergy, Asthma and Immunology (JCAAI) ST*AR Program AAAAI Assembly overview Allied Health Federation of the RSLAAI Societies International Military Allergy New Allergist/Immunologist Assembly Program Directors Organizational Chart Board of Directors Interest Sections Committees Fellows-in-Training Allied Health Professional Assembly Federation of RSLAAIS International Assembly Military Allergy Assembly New Allergist/Immunologist Assembly Program Directors Associates		Resources: Quick Reference Guide for Physicians: Evidence-Based Conclusions on Inhaled Steroid Treatment for Asthma Inhaled corticosteroid (ICS) therapy remains the gold standard of asthma treatment, according to findings from a systematic evidence review published by the American College of Chest Physicians (ACCP), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy, Asthma, and Immunology (ACAAI). Published in the December 2003 issue of CHEST, the review offers evidence-based conclusions on several prominent risks associated with ICS therapy for the treatment of adult and pediatric asthma. An expert panel with representatives from the AAAAI, the ACCP and the ACAAI identified critical questions that impact decisions regarding the use of ICS therapy in relation to the five adult and pediatric risk areas of bone mineral density (BMD), cataracts, glaucoma, growth retardation, and skin thinning. A consensus statement was provided for each risk area along with a grade to reflect the quantity and quality of evidence supporting each conclusion. Overall, the panel concluded that the benefits associated with ICS use greatly exceed the risks. Download the Quick Reference Guide below or order a reprint of the full paper by contacting Arlene Karavich at the ACCP via e-mail akaravich@chestnet.org or phone (847) 498-8358. Download the Quick Reference Guide (PDF) This page was last updated February, 2004. <back>
	© 1996-2008 · All Rights Reserved · American Academy of Allergy Asthma & Immunology